MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer

Ou, Chunlin; Sun, Zhenqiang; Li, Xiayu; Li, Xiaoling; Ren, Weiguo; Qin, Zailong; Zhang, Xuemei; Yuan, Weitang; Wang, Jia; Yu, Wentao; Zhang, Shiwen; Qiu, Ping; Yan, Qun; Xiong, Wei; Li, Guiyuan; Ma, Jian

doi:10.1016/j.canlet.2017.04.011

Cited by 102 publications

(101 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have found dysregulation of miR‐590‐5p in a number of different types of cancer cells . Thus, we examined the correlation of miRNA with disease progression of NSCLC.…”

Section: Resultsmentioning

confidence: 99%

“…Recently, cellular miR‐590‐5p has been shown to play important roles in tumorigenesis and metastasis of various cancers where it was shown to function as either a tumor suppressor or an oncomiR based on its target(s) in the respective cancers. Its expression was found to be downregulated in breast, hepatocellular, colorectal, and lung cancer tissues, and targeted the Wnt/β‐catenin pathway, SOX2 (SRY‐box 2), TGF‐βRII (transforming growth factor beta receptor 2), NF90/VEGFA (nuclear factor 90/vascular endothelial growth factor A) and GAB1 (GRB2 associated binding protein A) which promote cancer growth and progression . Likewise, miR‐590‐5p oncogenic properties were reported in gastric, cervical, vulvar, and clear cell renal cancer, where it targets RECK (reversion inducing cysteine rich protein with kazal motifs), CHL1 (close homolog of L1), TGF‐βRII, and PBRM1 (Polybromo 1), respectively, and regulates cell proliferation, migration and invasion of cancer cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Despite the availability of various diagnostic procedures, a tissue biopsy is still indispensable for the routine diagnosis of lung cancer. However, inaccurate diagnoses can occur, leading to inefficient cancer management. In this context, use of circulating microRNAs (miRNAs) may serve as diagnostic tools as liquid biopsies, and as biomarkers to better understand the molecular mechanisms involved in the progression of cancer. We identified miR‐590‐5p as a potential prognostic marker in the progression of non‐small cell lung cancer (NSCLC). We were able to detect this miRNA in blood plasma samples of NSCLC patients through quantitative real‐time PCR. Our data showed an ~7.5‐fold downregulation of miR‐590‐5p in NSCLC patients compared to healthy controls, which correlated with several clinicopathological features. Further, overexpression of miR‐590‐5p led to decreased cell viability, proliferation, colony formation, migration, and invasion potential of lung cancer cells, whereas its knockdown showed the opposite effect. In addition, the levels of several proteins involved in the epithelial‐to‐mesenchymal transition negatively correlated with miR‐590‐5p levels in lung adenocarcinoma cells and tumors of NSCLC patients. Further, dual‐luciferase reporter assays identified STAT3 as a direct target of miR‐590‐5p, which negatively regulated STAT3 activation and its downstream signaling molecules (eg, Cyclin D1, c‐Myc, Vimentin, and β‐catenin) involved in tumorigenesis. Taken together, our study suggests that miR‐590‐5p functions as a tumor suppressor in NSCLC through regulating the STAT3 pathway, and may serve as a useful biomarker for the diagnosis/prognosis of NSCLC, and as a potential therapeutic target for the treatment of NSCLC.

show abstract

“…Previous studies have found dysregulation of miR‐590‐5p in a number of different types of cancer cells . Thus, we examined the correlation of miRNA with disease progression of NSCLC.…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interestingly, NF2 is a sensor in the cell-cell contact inhibition of the Hippo signaling. [16] Figure 2H demonstrates that the expression of NF2 was gradually increased along with cancer cell density arising, while LINC00152 and YAP1 expression was decreased when cell density was arising. [16] Figure 2H demonstrates that the expression of NF2 was gradually increased along with cancer cell density arising, while LINC00152 and YAP1 expression was decreased when cell density was arising.…”

Section: Linc00152mentioning

confidence: 99%

“…[16] Suppression of YAP1 in CRC cell line, HCT116, caused downregulation of 288 genes, and those genes are involved in malignant proliferation and epithelial-mesenchymal transition (EMT), suggesting that YAP1 targeting genes play an important role in progression of CRC. [16] Suppression of YAP1 in CRC cell line, HCT116, caused downregulation of 288 genes, and those genes are involved in malignant proliferation and epithelial-mesenchymal transition (EMT), suggesting that YAP1 targeting genes play an important role in progression of CRC.…”

Section: Introductionmentioning

confidence: 99%

Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer

Sun

et al. 2019

Advanced Science

Self Cite

118

View full text Add to dashboard Cite

cancer-associated lncRNA (CCAL), [3] colon cancer-associated transcript 1 (CCAT1) and colon cancer-associated transcript 2 (CCAT2). [4] Since lncRNAs regulate a subset of genes, and are transcriptionally regulated by a series of transcription factors, targeting these lncRNAs induces a much greater effect on cancer cells than targeting single gene. [5] Therefore, exploring the upstream and downstream regulation mechanism of cancer-associated lncRNAs has been gaining widespread attention.As the main effector of the Hippo pathway, Yes-associated protein 1 (YAP1) plays a key role in regulating multiple biological function, including cell-cell contact inhibition, proliferation, and differentiation. [6,7] As a transcription coactivator, YAP1 is abnormally expressed in various malignancies, [8,9] and modulates biological phenotypes of cancer cells via regulating a number of target genes, such as CTGF, CYR61, and AREG. [7,8] Recently, a novel regulatory model of YAP1 transcriptionally regulating the noncoding RNAs (ncRNAs) in CRC has attracted much attention, in which of these noncoding RNAs, including microRNAs (miR-130a [10] and miR-29 [11] ), as well as lncRNAs (RMRP, [12] BCAR4, [13] MALAT1, [14] and lncARSR [15] ). However, the mechanism and As a transcription coactivator, Yes-associated protein 1 (YAP1)'s role in tumorigenesis is well established. However, the mechanism of YAP1-regulating long noncoding RNAs (lncRNA) in tumors is still largely unknown. Here, a YAP1 target gene, long intergenic noncoding RNA 00152 (LINC00152), which is highly expressed in colorectal cancer (CRC), is identified. The oncogenic functions of LINC00152 in CRC are demonstrated by a panel of in vitro and in vivo experiments. Further studies reveal the potential downstream mechanisms of LINC00152, which can act as a competing endogenous RNA sponging with miR-632 and miR-185-3p to regulate Fascin actin-bundling protein 1 (FSCN1) expression and thus promote the malignant proliferation and metastasis in CRC cells. Targeting the YAP1/LINC00152/ FSCN1 axis inhibits the progression of CRC. This finding provides a new regulatory model of the "YAP1-lncRNA" in CRC, which gives rise to a new perspective, "YAP1/LINC00152/miR-632-miR-185-3p/FSCN1," to explore the cancer-promoting mechanism of YAP1 involved in CRC.

show abstract

“…In the post-genomic era, non-coding RNAs (ncRNAs) have aroused great attention in chemistry and life sciences (1)(2)(3). Generally, ncRNAs are divided into two categories depended on the length of a transcript.…”

mentioning

confidence: 99%

Metastasis-associated lung adenocarcinoma transcript 1 regulates tumor progression: old wine in a new bottle

Yan

Kuang

et al. 2018

J. Thorac. Dis.

Self Cite

View full text Add to dashboard Cite

MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer

Cited by 102 publications

References 48 publications

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer

Metastasis-associated lung adenocarcinoma transcript 1 regulates tumor progression: old wine in a new bottle

Contact Info

Product

Resources

About